secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bioventus Inc. (BVS)
CIK:        0001665988
Form:       8-K
Filed at:   2025-01-03T23:59:59+00:00
Accession:  0001628280-25-000253
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 2.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioventus completes divestiture of Advanced Rehab business to Accelmed for $25M cash plus $20M earn-out
--------------------------------------------------------------------------------

- Closed sale of Advanced Rehabilitation business to Accelmed Partners on Dec 31, 2024.
- Received $25M cash at closing, subject to working capital adjustments.
- Up to $20M in earn-out payments based on 2025-2026 revenue and EBITDA thresholds.
- Net closing proceeds of approx $20M to enhance liquidity; company to focus on core businesses.
- Accelmed is a private equity firm focused on commercial-stage HealthTech companies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1665988/000162828025000253/0001628280-25-000253-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1665988/000162828025000253/bvs-20241231.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-000253

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer